Article Text

Download PDFPDF
Archivist
Azithromycin and cystic fibrosis

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Macrolides are commonly used in respiratory disease; they no doubt have an anti-inflammatory effect as well as their better-known bacteriostatic role. Three times a week prophylaxis seems to be a preferred regimen. Is there a role in cystic fibrosis in reducing inflammation and in turn reducing structural lung damage? Stick SM et al (Lancet Resp Medicine 2022; DOI: https://doi.org/10.1016/S2213-2600(22)00165-5) have hypothesised that azithromycin, given three times weekly to infants with cystic fibrosis from diagnosis until age 36 months, would reduce the extent of structural lung disease as captured on chest CT scans. This was a phase three, randomised, …

View Full Text

Footnotes

  • Provenance and peer review Commissioned; internally peer reviewed.